Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluate BORR in patients with previously treated Stage III (unresectable) or Stage IV melanoma receiving ipilimumab.

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

United States: Food and Drug Administration

Study ID:

CA184-008

NCT ID:

NCT00289627

Start Date:

March 2006

Completion Date:

July 2007

Related Keywords:

• Melanoma
• Previously treated melanoma
• Unresectable Stage III
• Stage IV
• Melanoma

Name	Location
Local Institution	Chicago, Illinois
Local Institution	Indianapolis, Indiana
Local Institution	Baltimore, Maryland
Local Institution	Bronx, New York
Local Institution	Portland, Oregon
Local Institution	Corona, California
Local Institution	Albuquerque, New Mexico
Local Institution	North Charleston, South Carolina
Local Institution	Austin, Texas
Local Institution	Arlington, Virginia
Local Institution	Chattanooga, Tennessee
Local Institution	Little Rock, Arkansas
Local Institution	Louisville, Kentucky
Local Institution	Las Vegas, Nevada